3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Breast Diseases
1
Interventions
pembrolizumab
25
Paclitaxel
20
Carboplatin
17
Bevacizumab
12
Specimen Handling
10
Letrozole
10
abemaciclib
7
dostarlimab
6
Taxes
6
Blood Specimen Collection
6
Medroxyprogesterone Acetate
5
Magnetic Resonance Spectroscopy
5
Fulvestrant
5
Drug Therapy
5
Doxorubicin
5
Cisplatin
5
Biopsy
5
olaparib
4
lenvatinib
4
atezolizumab
4
Radiotherapy
4
Progestins
4
Observation
4
Nivolumab
4
Megestrol Acetate
4
Immunoglobulin G
4
Gemcitabine
4
trastuzumab deruxtecan
3
palbociclib
3
X-Rays
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Endometrial Neoplasms
×
Imlunestrant
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled